| |||||||||||||||
15th PHV 2018 : 15th Pharmacovigilance 2018 | |||||||||||||||
Link: http://www.virtueinsight.com/pharma/15th-Pharmacovigilance-2018/ | |||||||||||||||
| |||||||||||||||
Call For Papers | |||||||||||||||
15th Annual Pharmacovigilance 2018 will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry. The entire program will cover the detection, analysis and prevention of adverse drug reactions. It will be studied with the help of case studies and industry experiences.
KEY SPEAKERS FROM Abbvie, Novo Nordisk, Abbott (USA), Roche, Sanofi, Pfizer, Novartis, Boehringer Ingelheim, Janssen Pharmaceutical, CSL Behring (USA), Isle of Man Government, Novartis, Roche, Bristol-Myers Squibb, Basilea Pharmaceuticals, Takeda Pharmaceuticals, MHRA, Boehringer Ingelheim KEY THEMES: Pharmacovigilance in 2020, Updates in PV, Brexit on Pharmacovigilance, Strategies for best practice , Market analysis , Implementing risk minimization procedures, Examining developments in GVP , Safety information , Medical devices, Good Pharmacovigilance practices, IT and new technologies for improvement of PV , Patient centric approach , PV Audit & inspections, Accelerating new medicine introduction in developing world and more. WHO SHOULD ATTEND:- CEO’s, CTO’s, CIO’s, Presidents, VPs, Directors, Heads, Managers, Scientific Advisors, Consultants of: Pharmacovigilance , Pharmacoepidemiology, Pharmacogenomics, Drug/Product Safety, Drug Development, Information and Clinical Data Management, Clinical Pharmacology, Clinical Safety, Periodical safety update Reports, Risk Management, Research & Development, Quality Assurance, Patient Safety, Signal Detection, Safety Surveillance, Outcomes Research, Data Analysis, Epidemiology, Medical Affairs, Regulatory Affairs and Compliance, Information technology, Sales, and Marketing Be a part of 15th Pharmacovigilance conference which will provide an important platform for pharmacovigilance stakeholders to discuss and share best practices in expediting pharmacovigilance development |
|